TARGRETIN

LOE Approaching

bexarotene

Bausch + Lomb
NDAORALCAPSULEPriority Review
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13

Mechanism of Action

Pharmacologic Class:

Retinoid

Clinical Trials (5)

NCT01578499Phase 3Completed

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Started Jun 2012
131 enrolled
Primary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma
NCT01504490Phase 1Terminated

Phase I Study of CS-7017 and Bexarotene

Started Dec 2011
9 enrolled
Solid TumorsLymphomaMultiple Myeloma
NCT01134341Phase 1Completed

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Started Mar 2010
34 enrolled
Cutaneous T-cell LymphomaMycosis FungoidesSezary Syndrome+1 more
NCT01007448Phase 4Completed

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

Started Jan 2010
59 enrolled
Refractory Cutaneous T-cell Lymphoma
NCT00411632Phase 2Completed

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Started Nov 2006
37 enrolled
Lung Cancer
Company
Bausch + Lomb
Bausch + Lomb
NJ - Bridgewater
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.